Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19
SARS-CoV-2 infection is clinically heterogeneous, ranging from asymptomatic to deadly.
SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs
The first step in SARS-CoV-2 genomic surveillance is testing to identify people who are infected. However, global testing rates are falling as we emerge from the acute health emergency and remain low in many low- and middle-income countries.
Risk of Type 1 Diabetes in Children is Not Increased after SARS-CoV-2 Infection: A Nationwide Prospective Study in Denmark
It has been hypothesized that SARS-CoV-2 infection in children can increase risk of developing type 1 diabetes.
"Protection against influenza and its complications in the context of Covid-19” symposium at Options XI
The Covid-19 pandemic has affected influenza circulation globally, surveillance is important to assess the upcoming season. Influenza is back!
Why Are Lots of Kids Likely to Be Sick This Holiday Season?
Opinion by Florian Krammer and Aubree Gordon
Navigating COVID language traps
Opinion by Dr. Peter M. Sandman.
Addressing COVID-19 vaccine hesitancy
This article seeks to summarize the currently available information to address the most common concerns regarding COVID-19 vaccination.
How COVID-19 shaped mental health: from infection to pandemic effects
The Coronavirus Disease 2019 (COVID-19) pandemic has threatened global mental health, both indirectly via disruptive societal changes and directly via neuropsychiatric sequelae after SARS-CoV-2 infection.
Older adults and COVID-19 vaccines
What do we know so far about older adults and COVID-19 vaccines? How long does the effect of the vaccine last and how successful have countries been in vaccinating older adults? WHO’s Dr Katherine O’Brien explains in Science in 5
The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2
As 2019 turned into 2020, a coronavirus spilled over from wild animals into people, sparking what has become one of the best documented pandemics to afflict humans.
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
The COVID-19 pandemic has been ongoing for more than 2 years now, and new variants such as Omicron are less susceptible to the vaccines developed against earlier lineages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).